Inventiva’s Lanifibranor On NASH Path After Phase II Success In NAFLD Patients With Diabetes
But All Eyes On NASH
The French biotech’s PPAR agonist has significantly reduced liver fat in non-alcoholic fatty liver patients with type 2 diabetes in a mid-stage trial, raising hopes for success in an ongoing pivotal program in non-alcoholic steatohepatitis.
